Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Linrodostat in Newly Diagnosed Glioblastoma
NCT04047706Phase 1Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Aug 2019
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of linrodostat in glioblastoma (GBM), sponsored by Northwestern University. Started Aug 2019; status: active, not recruiting.
02
Drugs
linrodostat
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04047706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047706.